- Anavex Life Sciences (AVXL, Financial) presented significant findings at the 9th International Conference on Alzheimer's Disease in Abu Dhabi.
- The presentation focused on Blarcamesine's mechanism in Alzheimer's treatment, specifically autophagy restoration via SIGMAR1 activation.
- The event emphasized region-specific healthcare delivery for Alzheimer's and related disorders in the MENA region.
Anavex Life Sciences Corp. (AVXL), a clinical-stage biopharmaceutical company, announced the presentation of key findings by Dr. Marwan Noel Sabbagh at the 9th International Conference on Alzheimer's Disease and Related Disorders held in Abu Dhabi, UAE, from April 18-20, 2025. Dr. Sabbagh is a Professor of Neurology at the Barrow Neurological Institute and the Chairman of Anavex's Scientific Advisory Board.
The presentation, titled “Oral Blarcamesine Novel Mechanism for Alzheimer Disease: Autophagy Restoration through Upstream SIGMAR1 Activation Clinical Efficacy Phase IIb/III Trial,” highlighted Blarcamesine’s innovative approach towards treating Alzheimer's disease. The drug candidate aims to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, showing promise in halting or reversing disease progression.
This high-profile conference gathered healthcare professionals, researchers, and advocates from the MENA region, USA, and Europe, all focused on advancing healthcare delivery for Alzheimer's disease and related disorders (ADRD) with an emphasis on regional disparities and solutions.
Anavex Life Sciences is committed to developing novel therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, and their flagship drug candidate ANAVEX®2-73 (blarcamesine) has progressed through multiple clinical trial phases, showcasing potential beyond Alzheimer's treatment, including indications like Parkinson’s disease and Rett syndrome.
